scholarly journals Comparison of the Efficacy of Gabapentin Versus Levodopa-C for the Treatment of Restless Legs Syndrome in End-Stage Renal Disease on Hemodialysis Patients

Cureus ◽  
2020 ◽  
Author(s):  
Muhammad Ali ◽  
Hina Iram ◽  
Fahad Nasim ◽  
Shafique A Solangi ◽  
Abdul Manan Junejo ◽  
...  
Keyword(s):  
Renal Disease ◽  
Restless Legs Syndrome ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
Restless Legs ◽  
Stage Renal Disease ◽  
End Stage

Clinical management of restless legs syndrome in end-stage renal disease patients

CNS Spectrums ◽  
2016 ◽  
Vol 22 (1) ◽  
pp. 14-21 ◽  
Author(s):  
Zeyad T. Sahli ◽  
Jae Jo ◽  
Shaker A. Mousa ◽  
Frank I. Tarazi
Keyword(s):  
Renal Disease ◽  
Restless Legs Syndrome ◽  
End Stage Renal Disease ◽  
Treatment Guidelines ◽  
Small Sample ◽  
Limited Information ◽  
Restless Legs ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Restless legs syndrome (RLS) is a common neurological movement disorder, characterized by restless and unpleasant sensations in the deep inside of legs. The symptoms of RLS are less noticeable during daytime, but more prevalent at night. Therefore, the disorder can induce low quality of life, insomnia, and impairment of daytime activity. RLS in end-stage renal disease (ESRD) patients is especially problematic due to premature discontinuation of dialysis and increased mortality. The prevalence of RLS among dialysis patients is much higher compared to the prevalence of the same disorder in patients with normal renal functions. Even though there are recommended treatment guidelines for the general population established by Medical Advisory Board of the RLS foundation, which include the use of dopamine agonists, levodopa, gabapentin, benzodiazepines, and opioids, limited information is available on the effects of these therapies in ESRD patients. Since the existing clinical data were extrapolated from small sample sizes in short-term clinical trials, further clinical studies are still needed to better assess the efficacy, safety, and tolerability of these medications in patients with ESRD.

Restless legs syndrome is associated with cardio/cerebrovascular events and mortality in end-stage renal disease

2014 ◽  
Vol 22 (1) ◽  
pp. 142-149 ◽  
Author(s):  
C.-H. Lin ◽  
H.-N. Sy ◽  
H.-W. Chang ◽  
H.-H. Liou ◽  
C.-Y. Lin ◽  
...  
Keyword(s):  
Renal Disease ◽  
Restless Legs Syndrome ◽  
End Stage Renal Disease ◽  
Restless Legs ◽  
Cerebrovascular Events ◽  
Stage Renal Disease ◽  
End Stage

Restless legs syndrome in end-stage renal disease: Clinical characteristics and associated comorbidities

2010 ◽  
Vol 11 (8) ◽  
pp. 785-790 ◽  
Author(s):  
Sonia Maria Holanda Almeida Araujo ◽  
Veralice Meireles Sales de Bruin ◽  
Lucas A. Nepomuceno ◽  
Marcos Lelio Maximo ◽  
Elizabeth de Francesco Daher ◽  
...  
Keyword(s):  
Renal Disease ◽  
Restless Legs Syndrome ◽  
End Stage Renal Disease ◽  
Clinical Characteristics ◽  
Restless Legs ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Rotigotine suppresses sleep-related muscle activity augmented by injection of dialysis patients’ sera in a mouse model of restless legs syndrome

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Kazuhiro Muramatsu ◽  
Sachiko Chikahisa ◽  
Noriyuki Shimizu ◽  
Hiroyoshi Séi ◽  
Yuichi Inoue
Keyword(s):  
Renal Disease ◽  
Restless Legs Syndrome ◽  
End Stage Renal Disease ◽  
Muscle Activity ◽  
Nrem Sleep ◽  
Healthy Population ◽  
Restless Legs ◽  
Leg Muscle ◽  
Stage Renal Disease ◽  
End Stage

Abstract Idiopathic restless legs syndrome (RLS) has a genetic basis wherein BTBD9 is associated with a higher risk of RLS. Hemodialysis patients also exhibit higher rates of RLS compared with the healthy population. However, little is known about the relationship of BTBD9 and end-stage renal disease to RLS pathophysiology. Here we evaluated sleep and leg muscle activity of Btbd9 mutant (MT) mice after administration of serum from patients with either idiopathic or RLS due to end-stage renal disease (renal RLS) and investigated the efficacy of treatment with the dopamine agonist rotigotine. At baseline, the amount of rapid eye movement (REM) sleep was decreased and leg muscle activity during non-REM (NREM) sleep was increased in MT mice compared to wild-type (WT) mice. Wake-promoting effects of rotigotine were attenuated by injection of serum from RLS patients in both WT and MT mice. Leg muscle activity during NREM sleep was increased only in MT mice injected with serum from RLS patients of ideiopatic and renal RLS. Subsequent treatment with rotigotine ameliorated this altered leg muscle activity. Together these results support previous reports showing a relationship between the Btbd9/dopamine system and RLS, and elucidate in part the pathophysiology of RLS.

158 RESTLESS LEGS SYNDROME IN END-STAGE RENAL DISEASE ON MAINTENANCE HEMODIALYSIS-CLINICAL CHARACTERISTICS

2009 ◽  
Vol 10 ◽  
pp. S43-S44
Author(s):  
S.M.H.A. Araújo ◽  
V.M.S. de Bruin ◽  
L.N. Barros ◽  
M.L.M. Pinho ◽  
E.F. Daher ◽  
...  
Keyword(s):  
Renal Disease ◽  
Restless Legs Syndrome ◽  
End Stage Renal Disease ◽  
Clinical Characteristics ◽  
Maintenance Hemodialysis ◽  
Restless Legs ◽  
Stage Renal Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document